Beyond Air® To Participate in the BTIG Virtual Biotechnology Conference 2024
July 16, 2024
Beyond Air® Reports Fiscal Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update
June 24, 2024
Beyond Air® Appoints David Webster as Chief Commercial Officer
June 13, 2024
Beyond Cancer Presents First-in-Class Clinical Data Showing an Immunogenic Response in Subjects with r/r Unresectable Solid Tumors Treated with Ultra-High Concentration Nitric Oxide (UNO)
June 3, 2024
Beyond Air® Schedules Fiscal Year End 2024 Financial Results Conference Call and Webcast
May 23, 2024
Beyond Cancer Selected to Present on the Clinical Development of Ultra-High Concentration Nitric Oxide (UNO) Therapy at the 2024 American Society of Clinical Oncology Annual Meeting
May 1, 2024
Beyond Air® Announces Pricing of $16.0 Million Registered Direct Offering of Common Stock and Warrants
March 20, 2024
Beyond Air® Reports Financial Results for Third Quarter of Fiscal Year 2024
February 12, 2024
Beyond Air® Schedules Third Fiscal Quarter 2024 Financial Results Conference Call and Webcast
January 18, 2024
Beyond Cancer™ Phase 1 Study Clears Cohort 1 in Patients with Advanced Relapsed or Refractory Unresectable Primary or Metastatic Cutaneous or Subcutaneous Solid Tumors
December 27, 2023

Sign up for updates from Beyond Air, Inc.

Unsubscribe from all email communications. Unsubscribe